IMCHECK THERAPEUTICS

ImCheck Therapeutics will present updated Phase I/II EVICTION trial data showing high complete remission rates when ICT01 is combined with azacitidine and venetoclax in newly diagnosed AML patients.

• ImCheck Therapeutics' ICT01, combined with azacitidine and venetoclax, demonstrates high complete remission rates in newly diagnosed AML patients. • The EVICTION trial's interim results highlight ICT01's safety and tolerability in older or unfit AML patients, including those with TP53 mutations. • ICT01, a novel γ9δ2 T-cell activator, targets butyrophilin 3A, enhancing anti-tumor immune responses in hematologic malignancies. • The Phase I/II study's findings will be presented at the 66th American Society of Hematology Annual Meeting, offering insights into ICT01's potential.

• The FDA granted Fast Track designation to ICT01 plus azacitidine and venetoclax for acute myeloid leukemia (AML) treatment in patients unfit for standard induction chemotherapy. • ICT01, a humanized anti-BTN3A monoclonal antibody, selectively activates gamma-delta T cells and is under evaluation in the phase 1/2a EVICTION trial. • Interim phase 1 data showed a strong safety profile and a 30% disease control rate, leading to a randomized dose-optimization cohort in October 2023. • The Fast Track designation may allow ImCheck Therapeutics more frequent FDA meetings, priority review, and accelerated approval.